By Product Type
Primary Antibodies
Recombinant Proteins
Other
By Research Area
Other
Timestamps of recording:
Dr John Maher: 02:25
Dr Matthias Bozza: 37:50
Dr John Lu: 59:45
Dr Rahul Mirlekar, Ms Maria Davern and Dr Ramona Moles have asked for their talks not to be included for intellectual property protection reasons.
On the 29th of April 2021, Proteintech held our first ever Early-Career Researcher Meeting for Cancer Immunology. It was a huge success, with researchers tuning in to watch our speakers from across the globe. All the speakers gave excellent talks, and in particular the impressive results in the ECR talks highlight the importance of supporting all scientists in their work and giving them opportunities to showcase their talents.
Dr. John MaherClinical Immunologist, Kings College London, UK |
 |
|
"CAR T-Cell Immunotherapy of Solid Tumors: Learning from the Clinic and Lab in Parallel" |
|
|
Dr John Maher is a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. He is also the scientific founder and chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital. |
Dr. John LuPresident and CEO of HebeCell, USA |
 |
|
"CAR-NK Cells from Engineered Pluripotent Stem Cells; Off-The-Shelf Therapeutics for All Patients" |
|
|
Dr. John Lu is currently the President and CEO of HebeCell Corporation. Established in 2016, HebeCell focuses on the fields of Immunotherapy and Regenerative Medicine. As a graduate from the Ontario Cancer institute, University of Toronto (PhD), John has 13 years of experience in cancer research. |
Dr. Eduardo BonavitaWe are pleased to announce Dr Eduardo Bonavita as session chair. Dr. Bonavita is a senior PostDoc at CRUK Manchester Institute in the laboratory of Dr. Santiago Zelenay where he is investigating the opposing role of inflammation during cancer. Dr Bonavita has published landmark studies addressing the role of inflammation in modulating anti-tumor immunity. |
 |
Dr. Matthias BozzaPostdoctoral Research Fellow, German Cancer Research Centre, Heidelberg, Germany "Non-viral, autonomously replicating DNA Nanovectors for T-cells engineering" |
 |
Dr. Rahul MirlekarPostdoctoral Research Fellow, University of North Carolina at Chapel Hill, USA "IL-35+ B cells establish immunosuppressive network in pancreatic ductal adenocarcinoma" |
 |
Maria DavernPhD Student, Trinity College Dublin, Ireland "The impact of major oncologic surgery on immune responses in the immediate post-operative setting in oesophageal adenocarcinoma patients; a guide to harnessing the double-edged sword of cancer surgery" |
 |
Dr. Ramona MolesPostdoctoral Research Fellow, National Cancer Institute, Bethesda, USA "Depletion of Innate Myeloid and NK cells exacerbates HTLV-1 infection and rescues the infectivity of the HTLV-1 orf-I knock-out virus" |
 |
For more information please email events@ptglab.com.
